<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391790</url>
  </required_header>
  <id_info>
    <org_study_id>MOSAIC</org_study_id>
    <secondary_id>DaBlaCa-16</secondary_id>
    <nct_id>NCT04391790</nct_id>
  </id_info>
  <brief_title>MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy</brief_title>
  <acronym>MOSAIC</acronym>
  <official_title>Randomized Controlled Trial With a MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy - MOSAIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jørgen Bjerggaard Jensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystectomy is the chosen treatment of bladder cancer in 400 cases every year in DK. In
      replacement of the removed bladder, a urinary diversion is constructed using 15cm of terminal
      ilium (Ad Modum Bricker).

      Ureteral strictures are diagnosed in 15% of the cystectomized patients, and these patients
      are at increased risk of infections, loss of renal function and repeated interventions. The
      left ureter is diagnosed with 70% of all strictures, presumably due to the construction of
      the urinary diversion.

      A modified urinary diversion have been tested in two small studies. The modified diversion is
      prolonged with 5cm compared to the conventional urinary diversion. The prolongation permits
      the urinary diversion to reach both the left and the right side of the abdomen, resulting in
      greater resection of non-viably distal ureter and less mobilization of the left ureter,
      lowering the rates of strictures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, multicenter, randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Strictures</measure>
    <time_frame>Within 2 years after cystectomy</time_frame>
    <description>Number of participants with benign strictures in the left ureter</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subject will cohere to current national guidlines with a cystectomy and standard urinary conduit ad modum Bricker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject in the interventional arm, will be treated with a cystectomy and modified retrosigmoid conduit</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cystectomy and modified urinary conduit</intervention_name>
    <description>The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Retrosigmoid conduit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cystectomy and standard urinary conduit ad modum Bricker</intervention_name>
    <description>The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Conventional ileal conduit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bladder cancer with the indication for robot assisted radical cystectomy

          -  Ileal conduit ad modum Bricker as planned urinary diversion

          -  Ability to understand the participant information orally and in writing

          -  Signed consent form

        Exclusion Criteria:

          -  Previous abdominal or pelvic radiotherapy

          -  Previous major abdominal surgery involving resection of bowel or construction of an
             enteric stoma

          -  Urostomy planned on the left side of the abdomen

          -  Single kidney

          -  Complete ureteral duplication (either uni- or bilaterally), known at time of inclusion

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jørgen Bjerggaard Jensen, Professor, DMSc</last_name>
    <phone>+45 78452617</phone>
    <email>Bjerggaard@skejby.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Brandt, MD</last_name>
    <email>simbra@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Urology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Knud Fabrin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Astrid Helene Livbjerg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Brandt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gitte Wrist Lam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Vangedal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Rigshospitalet</name>
      <address>
        <city>København</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulla Nordström Joensen, MD, PhD Assoc. Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thor Knak Jensen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Jørgen Bjerggaard Jensen</investigator_full_name>
    <investigator_title>Professor, Consultant, MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>ureteral strictures</keyword>
  <keyword>urinary diversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

